Secukinumab not checked
Novartis Pharmaceuticals · AIN457 low dose · AIN457 high dose
FollowEvery change as it happens, and a Monday email
Trials
9 active
61 in total · 16 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116. Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.”In the company’s words, NCT05622708 on ClinicalTrials.gov
- Tested for
- Non-radiographic Axial Spondyloarthritis, Hidradenitis Suppurativa (HS), Autoimmunity, Inflammation, Polymyalgia Rheumatica, Juvenile Psoriatic Arthritis
- Main trialPhase 4
- “This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP \< 1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.”In the company’s words, NCT05622708 on ClinicalTrials.gov
- Other names
- AIN457 low dose · AIN457 high dose · AIN457 · AIN457A · AIN457 300 mg · Cosentyx
Other drugs for Non-radiographic Axial Spondyloarthritis
- 6083SBio · Phase 3
- VilamakitugXBiotech, Inc. · Phase 2
Copies tested against it2
Other companies’ versions, mostly cheaper copies for when the patent ends
- CT-P55Celltrion · NCT07054970, NCT06630559
- BAT2306Bio-Thera Solutions · NCT04711343, NCT05377944 · finished
Coming up5
- 8 Feb 2028Phase 4 trial completes · ClinicalTrials.gov
- 8 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 25 Sep 2029Phase 4 trial completes · ClinicalTrials.gov
- 31 Oct 2029Phase 1 trial completes · ClinicalTrials.gov
- 29 Jan 2030Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials61
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 8 Feb 2028 | A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission | |
| Phase 4Recruiting | 25 Sep 2029 | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 4Recruiting | 29 Jan 2030 | Secukinumab Open Label Roll-over Extension Protocol | |
| Phase 3Active, not recruiting | 8 May 2028 | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | |
| Phase 1Recruiting | 31 Oct 2029 | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). | |
| Phase 4Completed | 26 Apr 2017 | Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis | |
| Phase 4Completed | 25 Apr 2018 | Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients | |
| Phase 4Completed | 5 Dec 2018 | Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo | |
| Phase 4Completed | 24 Sep 2019 | Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis | |
| Phase 4Completed | 11 Mar 2021 | Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis | |
| Phase 4Withdrawn | 24 Mar 2021 | An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound | |
| Phase 4Completed | 30 Nov 2021 | Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome | |
| Phase 4Completed | 30 Nov 2021 | Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | Apr 2013 | Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year | |
| Phase 3Completed | Jul 2013 | Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis | |
| Phase 3Completed | 7 Dec 2015 | Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis | |
| Phase 3Completed | 13 Dec 2018 | Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis | |
| Phase 3Completed | 15 Feb 2019 | SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis | |
| Phase 3Completed | 1 Jul 2019 | Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis | |
| Phase 3Completed | 13 Sep 2019 | Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis | |
| Phase 3Completed | 19 Sep 2019 | Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | 19 Nov 2019 | Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | 11 Dec 2019 | Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site | |
| Phase 3Completed | 30 Dec 2019 | Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis | |
| Phase 3Completed | 7 Oct 2020 | Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) | |
| Phase 3Completed | 10 Nov 2020 | Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) | |
| Phase 3Terminated | 29 Jun 2021 | A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) | |
| Phase 3Completed | 23 Sep 2021 | Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) | |
| Phase 3Completed | 1 Oct 2021 | This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). | |
| Phase 3Completed | 12 Nov 2021 | Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) | |
| Phase 3Completed | 17 Feb 2022 | Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA | |
| Phase 3Completed | 17 May 2022 | Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis | |
| Phase 3Completed | 2 Jun 2022 | Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo. | |
| Phase 3Terminated | 16 May 2023 | A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) | |
| Phase 3Completed | 26 May 2023 | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa | |
| Phase 3Terminated | 23 Aug 2023 | Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis | |
| Phase 3Terminated | 13 Sep 2023 | Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis | |
| Phase 3Completed | 3 Apr 2024 | Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis | |
| Phase 3Terminated | 17 Oct 2024 | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | |
| Phase 3Terminated | 17 Oct 2024 | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | |
| Phase 3Completed | 22 Oct 2024 | Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment | |
| Phase 3Completed | 7 Nov 2024 | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | |
| Phase 3Completed | 18 Dec 2024 | Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy | |
| Phase 3Completed | 11 Apr 2025 | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) | |
| Phase 3Completed | 10 Sep 2025 | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | |
| Phase 3Completed | 24 Feb 2026 | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | |
| Phase 3Withdrawn | 20 Mar 2028 | Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). | |
| Phase 2Terminated | 19 Aug 2010 | An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease | |
| Phase 2Completed | Nov 2012 | Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis | |
| Phase 2Completed | Dec 2012 | Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis | |
| Phase 2Terminated | 29 Jan 2013 | A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica | |
| Phase 2Completed | 2 Aug 2019 | Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy | |
| Phase 2Completed | 8 Jun 2021 | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis | |
| Phase 2Completed | 16 Nov 2021 | PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus | |
| Phase 1Completed | 12 Mar 2025 | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | |
| Phase 4Ended | not given | Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab) | |
| Phase 3Authorised | not given | A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis | |
| Phase 4Authorised | not given | Proactive therapeutic drug monitoring versus routine care with the novel biologics in psoriasis: a pragmatic, multicentric, randomised, controlled study (HELIOS) | |
| Phase 2Ended | not given | PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease | |
| Phase 4Authorised | not given | Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics. | |
| Phase 2Authorised | not given | STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026